• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

    2/13/25 2:00:00 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $IDXX alert in real time by email

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences:

    • Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate and CAG Finance, will participate in a fireside chat at the virtual BofA Securities Animal Health Summit.
    • Monday, March 3, 11:35 am – 12:05 pm EST – Jay Mazelsky, President and Chief Executive Officer, will present at the 46th Annual Raymond James Institutional Investors Conference.

    Live webcasts of the presentations will be available through links on the IDEXX website, www.idexx.com/investors. Archived editions of the presentations will be available via the same link.

    About IDEXX Laboratories, Inc.

    IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250213277671/en/

    Investor Relations

    [email protected]

    Get the next $IDXX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IDXX

    DatePrice TargetRatingAnalyst
    8/5/2025$545.00 → $785.00Buy
    BTIG Research
    7/1/2025$625.00Buy
    Jefferies
    12/2/2024$500.00Outperform
    Leerink Partners
    7/25/2024$580.00Buy
    BTIG Research
    1/30/2024$525.00Overweight → Neutral
    Piper Sandler
    12/7/2023$602.00Outperform
    Exane BNP Paribas
    12/4/2023Neutral → Buy
    Cleveland Research
    8/2/2023$610.00Overweight → Neutral
    Atlantic Equities
    More analyst ratings

    $IDXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on IDEXX Labs with a new price target

    BTIG Research reiterated coverage of IDEXX Labs with a rating of Buy and set a new price target of $785.00 from $545.00 previously

    8/5/25 10:21:27 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Jefferies initiated coverage on IDEXX Labs with a new price target

    Jefferies initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $625.00

    7/1/25 8:38:56 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Leerink Partners initiated coverage on IDEXX Labs with a new price target

    Leerink Partners initiated coverage of IDEXX Labs with a rating of Outperform and set a new price target of $500.00

    12/2/24 6:57:33 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    SEC Filings

    View All

    SEC Form 10-Q filed by IDEXX Laboratories Inc.

    10-Q - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    8/4/25 4:22:36 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    8/4/25 6:30:59 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)

    7/10/25 7:00:41 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IDEXX Laboratories Announces Second Quarter Results

    Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic. Advances IDEXX's innovation agenda and continues strong global commercial execution, resulting in record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx™ placements. Delivers EPS of $3.63, an increase of 49% as reported, and 17% on a comparable basis, net of $0.56 EPS growth benefit from comparison to prior year period discrete litigation expense accrual, and including $0.07 benefit from a discrete tax reserve release. Increases 2025 revenue guidance to $4,205 million - $4,280 million, an increas

    8/4/25 6:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals

    WESTBROOK, Maine, July 30, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today released its 2024 Corporate Responsibility Report "Enhancing the health and well-being of pets, people, and livestock" highlighting progress toward goals closely aligned with its Purpose and business strategy. The Care We AdvanceIDEXX brings clarity to the complex world of veterinary medicine through innovative diagnostic and software solutions. Key highlights from the report include the following: Significantly advanced our innovation str

    7/30/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro

    7/10/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Leadership Updates

    Live Leadership Updates

    View All

    IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. "Jay is an accomplished executive who brings extensive strategic thinking and financial leadership experience, along with investor perspective, from his tenure leading State Street during a period of global growth and technological transformation. Given his substantial public company board and corporate governance experience and his unique backgro

    7/10/25 7:00:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    First Watch Announces Appointment of Irene Chang Britt to Board of Directors

    BRADENTON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ:FWRG) ("First Watch" or the "Company"), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Irene Chang Britt to its Board of Directors, effective immediately. Ms. Chang Britt is an experienced independent board director and former Fortune 500 C-suite executive, who currently serves on the boards of established businesses and start-up companies representing a variety of industries, including retail, CPG, e-commerce and lifestyle. "We are thrilled to welcome Irene to the Board of Directors of First Watch, and I'm confident that our company wil

    7/19/23 4:15:00 PM ET
    $BHF
    $FWRG
    $IDXX
    Life Insurance
    Finance
    Restaurants
    Consumer Discretionary

    Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company's Board of Directors effective September 20, 2021. "We are excited to welcome Merilee to our Board of Directors," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "Merilee brings a wealth of operational, financial, and business experience to our team. Having started as employee #11 at IDEXX, she helped to drive a multitude of innovative growth strategies and successfully scaled the business from sta

    9/22/21 8:00:00 AM ET
    $IDXX
    $OCUL
    $TMDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $IDXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Erickson Michael G sold $263,813 worth of shares (406 units at $649.96), decreasing direct ownership by 3% to 11,287 units (SEC Form 4)

    4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    8/14/25 6:01:09 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 5 filed by Erickson Michael G

    5/A - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    8/14/25 6:00:34 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: New insider Erickson Michael G claimed ownership of 9,377 shares (SEC Form 3)

    3/A - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)

    8/14/25 6:00:06 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    11/12/24 3:48:28 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEXX Laboratories Inc.

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    11/4/24 11:47:05 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by IDEXX Laboratories Inc. (Amendment)

    SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)

    2/13/24 5:06:19 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $IDXX
    Financials

    Live finance-specific insights

    View All

    IDEXX Laboratories Announces Second Quarter Results

    Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic. Advances IDEXX's innovation agenda and continues strong global commercial execution, resulting in record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx™ placements. Delivers EPS of $3.63, an increase of 49% as reported, and 17% on a comparable basis, net of $0.56 EPS growth benefit from comparison to prior year period discrete litigation expense accrual, and including $0.07 benefit from a discrete tax reserve release. Increases 2025 revenue guidance to $4,205 million - $4,280 million, an increas

    8/4/25 6:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories to Release 2025 Second Quarter Financial Results

    IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 second quarter financial results for Monday, August 4, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q2 2025 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen

    6/24/25 1:00:00 PM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IDEXX Laboratories Announces First Quarter Results

    Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by benefits from IDEXX execution drivers, including continued solid new business gains and strong year-over-year global premium instrument installed base growth, including over 300 IDEXX inVue Dx™ placements. Delivers EPS of $2.96, an increase of 5% as reported and 7% on a comparable basis, supported by gross margin expansion of 90 basis points as reported and 80 basis points on a comparable basis. Adjusts 2025 revenue guidance to $4,095 million - $4,210 million, an increase of $40 million

    5/1/25 6:30:00 AM ET
    $IDXX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care